
USFDANov 20, 2026, 07:56 PM
Capricor Therapeutics Receives FDA Complete Response Letter for Deramiocel
AI Summary
Capricor Therapeutics announced it received a Complete Response Letter (CRL) from the FDA for its resubmitted Biologics License Application (BLA) for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD). The FDA cited insufficient data for substantial evidence of effectiveness and other clinical deficiencies. The company plans to review the letter and determine next steps. Capricor has approximately $198.5 million in cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2026, sufficient for at least the next 12 months, and is reviewing operating costs to extend its cash runway.
Key Highlights
- Capricor Therapeutics received a Complete Response Letter from the FDA for its Deramiocel BLA for Duchenne muscular dystrophy.
- FDA cited insufficient data for substantial evidence of effectiveness and other clinical deficiencies.
- Company has approximately $198.5 million in cash and equivalents as of September 30, 2026, sufficient for at least 12 months.
- Capricor is reviewing operating costs to extend its cash runway.
- A conference call and webcast are scheduled for Monday, November 23, at 8:30 a.m. ET to discuss the CRL.
Price Impact
More from CAPR